Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic

Papadimitriou-Olivgeris, Matthaios; Kolonitsiou, Fevronia; Kefala, Sotiria; Spiliopoulou, Anastasia; Αρέθα, Διαμάντω; Bartzavali, Christina; Siapika, Argyro; Marangos, Markos; Fligou, Fotini

doi:10.1016/j.bjid.2022.102353

Cited by 23 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, the incidence of non-C. albicans candidemia has increased. This finding is consistent with a previous study, 3 and this increase probably occurred due to the overuse of antibiotics, concurrent corticosteroids, and/or immunomodulatory agents. 9 Second, we observed prolonged catheter duration and a suboptimal level of compliance with IPC policies, particularly for maintenance bundles.…”

supporting

confidence: 93%

“…1,2 Previous studies have suggested that non-C. albicans candidemia has increased during the coronavirus disease 2019 (COVID-19) pandemic, probably due to the increasing use of central venous catheters, suboptimal catheter care, and concurrent corticosteroid use. [3][4][5] Candida parapsilosis bloodstream infection (BSI) has been associated with the overuse of central venous catheters and receipt of parenteral nutrition, and risk factors for Candida tropicalis are poorly defined. 6,7 Overall, the C. parapsilosis and C. tropicalis BSI incidence rates at Thammasat University Hospital increased from 0.42% to 2.24% and from 1.68% to 7.46% between 2019 and 2021, respectively, whereas the rate of C. albicans BSI remained stable at 6.70%-7.83%.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Increase in the incidence of Candida parapsilosis and Candida tropicalis bloodstream infections during the coronavirus disease 2019 (COVID-19) pandemic

Pienthong

Visuttichaikit²,

Apisarnthanarak³

et al. 2023

ASHE

View full text Add to dashboard Cite

To the Editor-Nosocomial candidemia is associated with substantial mortality, longer hospital stays, and higher healthcare costs. The mortality among patients with candidemia remains high and is associated with increasing in incidence of non-Candida albicans Candida spp. 1,2 Previous studies have suggested that non-C. albicans candidemia has increased during the coronavirus disease 2019 (COVID-19) pandemic, probably due to the increasing use of central venous catheters, suboptimal catheter care, and concurrent corticosteroid use. [3][4][5] Candida parapsilosis bloodstream infection (BSI) has been associated with the overuse of central venous catheters and receipt of parenteral nutrition, and risk factors for Candida tropicalis are poorly defined. 6,7 Overall, the C. parapsilosis and C. tropicalis BSI incidence rates at Thammasat University Hospital increased from 0.42% to 2.24% and from 1.68% to 7.46% between 2019 and 2021, respectively, whereas the rate of C. albicans BSI remained stable at 6.70%-7.83%. We performed a case-case-control study to identify risk factors for and outcomes of C. parapsilosis and C. tropicalis BSIs at Thammasat University Hospital (Pathum Thani, Thailand), a tertiary-care center.For the period from January 1, 2019, through December 31, 2021, we evaluated the risk factors and outcomes of C. parapsilosis and C. tropicalis BSIs compared with C. albicans BSI using the case 1-case 2-control method. Study participants were identified from the microbiology laboratory database, which includes all positive blood cultures for all Candida spp. Case 1 was defined as patients with C. parapsilosis BSI. Case 2 was defined as patients with C. tropicalis BSI. Controls were patients with C. albicans BSI. A BSI was defined as isolation of the Candida species of interest from at least 1 peripheral venous sample or central venous sampling. Blood samples were processed using an automated BACTEC-NR system (Becton Dickinson, Franklin Lakes, NJ).

show abstract

supporting

confidence: 93%

mentioning

confidence: 99%

Increase in the incidence of Candida parapsilosis and Candida tropicalis bloodstream infections during the coronavirus disease 2019 (COVID-19) pandemic

Pienthong

Visuttichaikit²,

Apisarnthanarak³

et al. 2023

ASHE

View full text Add to dashboard Cite

show abstract

“…Candidemia, which exhibited a high mortality rate ranging from 30% to 60% in clinical studies conducted before the COVID pandemic, 7–9 as garnered renewed attention in the context of COVID. There have been reports on the increased incidence of candidemia following COVID, as well as the identification of risk factors associated with candidemia and studies on mortality 10–12 …”

Section: Introductionmentioning

confidence: 99%

“…There have been reports on the increased incidence of candidemia following COVID, as well as the identification of risk factors associated with candidemia and studies on mortality. [10][11][12] In this groundbreaking international study, our primary focus was to comprehensively investigate the clinical outcomes that emerge from the intricate connection between COVID-19 and candidemia. By meticulously analysing this relationship, we aimed to gain deep insights into the factors that actively contribute to mortality, thereby enhancing our understanding of this complex phenomenon.…”

Section: Introductionmentioning

confidence: 99%

Understanding clinical outcomes and factors influencing mortality in intensive care unit patients with COVID‐19‐associated candidemia

Aydın,

Mert,

Yılmaz

et al. 2024

Mycoses

View full text Add to dashboard Cite

BackgroundDuring the COVID pandemic, research has shown an increase in candidemia cases following severe COVID infection and the identification of risk factors associated with candidemia. However, there is a lack of studies that specifically explore clinical outcomes and mortality rates related to candidemia after COVID infection.ObjectivesThe aim of this international study was to evaluate the clinical outcomes and identify factors influencing mortality in patients who developed candidemia during their COVID infection.Patients/MethodsThis study included adult patients (18 years of age or older) admitted to the intensive care unit (ICU) and diagnosed with COVID‐associated candidemia (CAC). The research was conducted through ID‐IRI network and in collaboration with 34 medical centres across 18 countries retrospectively, spanning from the beginning of the COVID pandemic until December 2021.ResultsA total of 293 patients diagnosed with CAC were included. The median age of the patients was 67, and 63% of them were male. The most common Candida species detected was C. albicans. The crude 30‐day mortality rate was recorded at 62.4%. The logistic regression analysis identified several factors significantly impacting mortality, including age (odds ratio [OR] 1.04, 95% confidence interval [CI] 1.02–1.07, p < .0005), SOFA score (OR 1.307, 95% CI 1.17–1.45, p < .0005), invasive mechanical ventilation (OR 7.95, 95% CI 1.44–43.83, p < .017) and duration of mechanical ventilation (OR 0.98, 95% CI 0.96–0.99, p < .020).ConclusionsBy recognising these prognostic factors, medical professionals can customise their treatment approaches to offer more targeted care, leading to improved patient outcomes and higher survival rates for individuals with COVID‐associated candidemia.

show abstract

“…Hospitalized patients are at risk for acquiring healthcare‐associated infections, such as candidiasis. People with candidemia were always more likely to have immune system‐suppressing drugs and less likely to have certain chronic disorders [6]. In immunocompromised patients, cryptococcus neoformans is also linked with parasitic illness.…”

Section: Introductionmentioning

confidence: 99%

QSPR analysis through graph models for predicting ADMET properties of antifungal drugs to treat fungal diseases

Parveen,

Balamurugan

2023

Int J of Quantum Chemistry

View full text Add to dashboard Cite

The chemical structure of a drug is considered as a chemical graph where the vertex set is the set of atoms and the edge set is the set of bonds between the atoms. Fungi‐related diseases are becoming a more serious medical problem as a result of changes in the worldwide environment. In this article, the QSPR analysis is performed to predict the ADMET properties of the drugs used to treat fungal infections such as mucormycosis, blastomycosis, invasive candidiasis, talaromycosis, cryptococcus, neoformans, and so forth. The antifungal drugs posaconazole, isavuconazole, and amphotericin B and its analogs are considered to carry out the QSPR analysis. The domination numbers of these drugs are determined to correlate with their ADMET properties through cubic regression and the analysis suggests a high association between the domination numbers of drugs and their ADMET properties. The ADMET properties of the analog structures of the drug amphotericin B are also predicted in this QSPR analysis.

show abstract

Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic

Cited by 23 publications

References 17 publications

Increase in the incidence of Candida parapsilosis and Candida tropicalis bloodstream infections during the coronavirus disease 2019 (COVID-19) pandemic

Increase in the incidence of Candida parapsilosis and Candida tropicalis bloodstream infections during the coronavirus disease 2019 (COVID-19) pandemic

Understanding clinical outcomes and factors influencing mortality in intensive care unit patients with COVID‐19‐associated candidemia

QSPR analysis through graph models for predicting ADMET properties of antifungal drugs to treat fungal diseases

Contact Info

Product

Resources

About